

DAFTAR PUSTAKA

- Adhiatma, A.T., Wahab, Z., dan Widyantara, I.F.E., 2017. Analisis Faktor-Faktor yang Berhubungan dengan Kejadian Gagal Ginjal Kronik Pada Pasien Hemodialisis Di RSUD Tugurejo Semarang. *Jurnal Kedokteran Muhammadiyah*, **5**: .
- Adiatma, D.C., 2014. Prevalensi dan Jenis Anemia Pada Pasien Penyakit Ginjal Kronik yang Menjalani Hemodialisis Reguler (Studi Di RSUP Kariadi Semarang). *Jurnal Media Medika Muda*, **16**.
- Adnan, A., Dania, H., dan Supadmi, W., 2018. Evaluasi terapi erythropoetin pada pasien hemodialisa di rumah sakit PKU Muhammadiyah Yogyakarta. *Pharmaciana*, **8**: 282.
- Ahsan, M.N., Asif, N., Khanzada, S.W., Asghar, M.S., Yasmin, F., Khalid, F., dkk., 2021. Comparative effectiveness of erythropoietin alpha and beta in hemodialysis patients: a single-center prospective observational study. *Journal of Community Hospital Internal Medicine Perspectives*, **11**: 782–786.
- Alicic, R.Z., Rooney, M.T., dan Tuttle, K.R., 2017. Diabetic Kidney Disease: Challenges, Progress, and Possibilities. *Clinical Journal of the American Society of Nephrology*, **12**: 2032–2045.
- AlKharboush, H., Alshehri, F., Alatwi, I., Al Karni, K., Alatawi, A., dan Hamdan, A.M., 2020. The Cost-Effectiveness of Using Epoetin-Beta Versus Darbepoetin-Alfa for the Treatment of Anemia Among Chronic Hemodialysis Patients. *Cureus*, .

Anandabaskar, N., 2019. Pharmacoeconomics, dalam: Raj, G.M. dan Raveendran, R. (Editor), *Introduction to Basics of Pharmacology and Toxicology: Volume 1: General and Molecular Pharmacology: Principles of Drug Action*. Springer, Singapore, hal. 297–301.

Andayani, T.M., 2013. Farmakoekonomi Prinsip dan Metodologi. *Yogyakarta: Bursa Ilmu*, .

Anees, M., Hameed, F., Mumtaz, A., Ibrahim, M., dan Khan, M.N.S., 2011. Dialysis-Related Factors Affecting Quality of Life in Patients on Hemodialysis **5**: 6.

Aryani, A.D., Kurdi, F.N., dan Soebyakto, B.B., 2016. Cost Effectiveness Analysis (CEA) Program Pengelolaan Penyakit Kronis (PROLANIS) Diabetes Melitus Tipe 2 Peserta JKN di Kota Serang Banten. *Jurnal Kedokteran dan Kesehatan : Publikasi Ilmiah Fakultas Kedokteran Universitas Sriwijaya*, **3**: 146–154.

Azmandian, J., Abbasi, M.R., Pourfarziani, V., Nasiri, A.A., Ossareh, S., Ezzatzadegan Jahromi, S., dkk., 2018. Comparing Therapeutic Efficacy and Safety of Epoetin Beta and Epoetin Alfa in the Treatment of Anemia in End-Stage Renal Disease Hemodialysis Patients. *American Journal of Nephrology*, **48**: 251–259.

Babitt, J.L. dan Lin, H.Y., 2012. Mechanisms of Anemia in CKD. *Journal of the American Society of Nephrology*, **23**: 1631–1634.

Banzi, R. dan Gerardi, C., 2016. *Application for Erythropoietin-Stimulating Agents (Erythropoietin Type Blood Factors) Version 3*. WHO EML 2016-

2017.

Bikbov, B., Purcell, C.A., Levey, A.S., Smith, M., Abdoli, A., Abebe, M., dkk.,

2020. Global, regional, and national burden of chronic kidney disease,

1990–2017: a systematic analysis for the Global Burden of Disease Study

2017. *The Lancet*, **395**: 709–733.

Brown, L.J., Clark, P.C., Armstrong, K.A., Liping, Z., dan Dunbar, S.B., 2010.

Identification of Modifiable Chronic Kidney Disease Risk Factors by

Gender In an African-American Metabolic Syndrome Cohort. *Nephrology*

nursing journal: journal of the American Nephrology Nurses'

Association, **37**: 133–142.

Capelli, I., Cianciolo, G., Gasperoni, L., Zappulo, F., Tondolo, F., Cappuccilli,

M., dkk., 2019. Folic Acid and Vitamin B12 Administration in CKD, Why

Not? *Nutrients*, **11**: 383.

Carrero, J.J., 2010. Gender Differences in Chronic Kidney Disease:

Underpinnings and Therapeutic Implications. *Kidney and Blood Pressure*

Research, **33**: 383–392.

Carson, J.L., Guyatt, G., Heddle, N.M., Grossman, B.J., Cohn, C.S., Fung, M.K.,

dkk., 2016. Clinical Practice Guidelines From the AABB: Red Blood Cell

Transfusion Thresholds and Storage. *JAMA*, **316**: 2025.

Cases, A., Egocheaga, M.I., Tranche, S., Pallarés, V., Ojeda, R., Górriz, J.L., dkk.,

2018. Anemia of chronic kidney disease: Protocol of study, management

and referral to Nephrology. *Nefrología (English Edition)*, **38**: 8–12.

CDC, 2021. Chronic Kidney Disease in the United States 2021. *Atlanta, GA: US*

Department of Health and Human Services, Centers for Disease Control and Prevention, 4.

Chae, J.-W., Song, C.S., Kim, H., Lee, K.-B., Seo, B.-S., dan Kim, D.-I., 2011.

Prediction of Mortality in Patients Undergoing Maintenance Hemodialysis by Charlson Comorbidity Index Using ICD-10 Database. *Nephron Clinical Practice*, **117**: 379–384.

Cheer, S.M. dan Wagstaff, A.J., 2004. Epoetin Beta. *Drugs*, **64**: 323–346.

Cheung, K., Teichert, M., Moll, H.A., Stricker, B.H., dan Visser, L.E., 2018.

Filled prescriptions of age-related contraindicated drugs in children: a one-year nationwide cohort study in the Netherlands. *International Journal of Clinical Pharmacy*, **40**: 1137–1143.

Cianciolo, G., De Pascalis, A., Di Lullo, L., Ronco, C., Zannini, C., dan La

Manna, G., 2017. Folic Acid and Homocysteine in Chronic Kidney Disease and Cardiovascular Disease Progression: Which Comes First. *Cardiorenal Medicine*, **7**: 255–266.

de Boer, I.H., Caramori, M.L., Chan, J.C.N., Heerspink, H.J.L., Hurst, C., Khunti,

K., dkk., 2020. KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. *Kidney International*, **98**: S1–S115.

Edejer, T.T.-T., Baltussen, R., Adam, T., Hutubessy, R., Acharya, A., Evans,

D.B., dkk. (Editor), 2003. *Making Choices In Health: WHO Guide To Cost-Effectiveness Analysis*. World Health Organization, Geneva.

Escudero-Vilaplana, V., Martínez-Nieto, C., López-Gómez, J.M., Vega-Martínez,

- A., Bellón-Cano, J.M., dan Sanjurjo-Sáez, M., 2013. Erythropoiesis-stimulating agents in anaemia due to chronic kidney disease: a cost-minimization analysis. *International Journal of Clinical Pharmacy*, **35**: 463–468.
- Garini, A., 2019. Kadar Hemoglobin Pada Pasien Gagal Ginjal Kronik Yang Menjalani Hemodialisis. *JPP (Jurnal Kesehatan Poltekkes Palembang)*, **13**: 111–116.
- Gray, A.M., Clarke, P.M., Wolstenholme, J.L., dan Wordsworth, S., 2011. *Applied Methods of Cost-Effectiveness Analysis in Healthcare*. OUP Oxford.
- Gunaseelan, R., Surudarma, I.W., Wihandani, D.M., dan Sutadarma, I.W.G., 2020. Prevalence of anemia on chronic kidney disease and its influenced factors in Sanglah General Hospital 2015-2017, Bali. *Intisari Sains Medis*, **11**: 248.
- Hahr, A.J. dan Molitch, M.E., 2021. Management of Diabetes Mellitus in Patients With CKD: Core Curriculum 2022. *American Journal of Kidney Diseases*, S0272638621007629.
- Harrison, T.R., Fauci, A.S., Braunwald, E., Kasper, D.L., Hauser, S.L., Longo, D.L., dkk., 2011. *Harrison's Manual Of Medicine*. McGraw Hill Professional, New York.
- Hidayati, Nugroho, A.E., dan Inayati, 2011. Evaluasi Penggunaan Terapi Anemia Pada Pasien ASKES Dengan Gagal Ginjal Kronik Yang Menjalani Hemodialisi Rutin Di RS PKU Muhammadiyah Yogyakarta. *Jurnal*

Manajemen dan Pelayanan Farmasi, **Vol. 1 No. 3**: 147–152.

Hofmann, M. dan Valliant, 2013. Managing dialysis patients who develop anemia caused by chronic kidney disease: focus on peginesatide. *International Journal of Nanomedicine*, 3297.

Huang, Y., Gou, R., Diao, Y., Yin, Q., Fan, W., Liang, Y., dkk., 2014. Charlson comorbidity index helps predict the risk of mortality for patients with type 2 diabetic nephropathy. *Journal of Zhejiang University. Science. B*, **15**: 58–66.

Icks, A., Haastert, B., Gandjour, A., Chernyak, N., Rathmann, W., Giani, G., dkk., 2010. Costs of dialysis-A regional population-based analysis. *Nephrology Dialysis Transplantation*, **25**: 1647–1652.

Inker, L.A., Astor, B.C., Fox, C.H., Isakova, T., Lash, J.P., Peralta, C.A., dkk., 2014. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. *American Journal of Kidney Diseases: The Official Journal of the National Kidney Foundation*, **63**: 713–735.

Insani, N., Manggau, M.A., dan Kasim, H., 2018. Analisis Efektivitas Terapi Pada Pasien Anemia Gagal Ginjal Hemodialisis Di Rsup Dr. Wahidin Sudirohusodo Makassar. *Majalah Farmasi dan Farmakologi*, **22**: 13–15.

International Society of Nephrology, 2013. Definition and classification of CKD. *Kidney International Supplements*, **3**: 19–62.

Jankowski, J., Floege, J., Fliser, D., Böhm, M., dan Marx, N., 2021. Cardiovascular Disease in Chronic Kidney Disease: Pathophysiological

Insights and Therapeutic Options. *Circulation*, **143**: 1157–1172.

Kandarini, Y., 2017. 'Penatalaksanaan Anemia Pada Penyakit Ginjal Kronik', .

Dipresentasikan pada PKB-Trigonum Sudema-Ilmu PenyakitT Dalam XXV.

KDIGO, 2012. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease.

KEMENKES RI, 2013. 'Profil Kesehatan Indonesia 2013', . URL: <https://pusdatin.kemkes.go.id/resources/download/pusdatin/profil-kesehatan-indonesia/profil-kesehatan-indonesia-2013.pdf> (diakses tanggal 24/3/2021).

KEMENKES RI, 2016. PMK No. 52 Tahun 2016 Tentang Standar Tarif Pelayanan Kesehatan Dalam Penyelenggaraan JKN.

Ku, E., Lee, B.J., Wei, J., dan Weir, M.R., 2019. Hypertension in CKD: Core Curriculum 2019. *American Journal of Kidney Diseases*, **74**: 120–131.

Lee, Prof.K.K.C., Bahri, Dr.S., Talib, Mdm.A., Zainuddin, Dr.J., Aljunid, Prof.D.Dr.S.M., Sulong, Prof.M.Dr.S., dkk., 2012. *Pharmacoeconomic Guideline For Malaysia*. Pharmaceutical Services Divison; Ministry Of health Malaysia, Malaysia.

Loughnan, A., Ali, G.R., dan Abeygunasekara, S.C., 2011. Comparison of the Therapeutic Efficacy of Epoetin Beta and Epoetin Alfa in Maintenance Phase Hemodialysis Patients. *Renal Failure*, **33**: 373–375.

Mak, R.H., 2008. Insulin and its role in chronic kidney disease. *Pediatric Nephrology (Berlin, Germany)*, **23**: 355–362.

- Mallappallil, M., Friedman, E.A., Delano, B.G., McFarlane, S.I., dan Salifu, M.O., 2014. Chronic kidney disease in the elderly: evaluation and management. *Clinical practice (London, England)*, **11**: 525–535.
- Marriott, J., Cockwell, P., dan Stringe, S., 2019. Chronic Kidney Disease and End-Stage Renal Disease, dalam: Whittlesea, C. dan Hodson, K. (Editor), *Clinical Pharmacy and Therapeutics*. Elsevier, Publication place not identified, hal. 294–316.
- MDCalc, 2021. 'Charlson Comorbidity Index (CCI)', *MDCalc*. URL: <https://www.mdcalc.com/charlson-comorbidity-index-cci> (diakses tanggal 7/12/2021).
- Meyer, T.W., Hostetter, T.H., dan Watnick, S., 2020. Twice-Weekly Hemodialysis Is an Option for Many Patients in Times of Dialysis Unit Stress. *Journal of the American Society of Nephrology*, **31**: 1141–1142.
- Mimura, I., Tanaka, T., dan Nangaku, M., 2015. How the Target Hemoglobin of Renal Anemia Should Be? *Nephron*, **131**: 202–209.
- Murtisiwi, L., 2019. Perbandingan Kualitas Hidup Pasien yang Menjalani Hemodialisis dengan Terapi Epoetin Alfa dan Epoetin Beta di RS PKU Muhammadiyah Yogyakarta. *Jurnal Farmasi (Journal of Pharmacy)*, **4**: 25.
- NICE, 2013. Guide To The Methods Of Technology Appraisal 2013.
- Nursalim, A., Siregar, P., dan Widyahening, I.S., 2013. Effect of Folic Acid, Vitamin B6 and Vitamin B12 Supplementation on Mortality and Cardiovascular Complication among Patients with Chronic Kidney

Disease: an Evidence-based Case Report. *Acta Medica Indonesiana*, **45**: 150–156.

Oh, S.W. dan Han, S.Y., 2015. Loop Diuretics in Clinical Practice. *Electrolytes & Blood Pressure : E & BP*, **13**: 17–21.

Oktiadewi, A.A.A.P., 2012. 'Hubungan Kadar Hemoglobin dan Status Gizi dengan Kualitas Hidup Pasien Penyakit Ginjal Kronik Stadium 5 yang Menjalani Hemodialisis.', . Universitas Diponegoro, Semarang.

O'Mara, N.B., 2008. Anemia in Patients With Chronic Kidney Disease. *Diabetes Spectrum*, , Volume 21, Number 1, 2008 **21**: 8.

Omrani, H.-R., Golmohhamadi, S., Hashemian, A.-H., Vaysmoradi, A.-Z., dan Safari-Faramani, R., 2018. Therapeutic efficacy of erythropoietin alfa and erythropoietin beta in hemodialysis; a randomized controlled trial. *Journal of Renal Injury Prevention*, **8**: 44–49.

Patel, S. dan Patel, J., 2021. *Epoetin Alfa*, StatPearls [Internet]. StatPearls Publishing.

PERNEFRI, 2011. Konsensus Manajemen Anemia Pada Penyakit Ginjal Kronik.

Pongsibidang, G.S., 2017. Risiko Hipertensi, Diabetes, dan Konsumsi Minuman Herbal Pada Kejadian Gagal Ginjal Kronik Di RSUP Dr Wahidin Sudirohusodo Makassar Tahun 2015. *Jurnal Wiyata: Penelitian Sains dan Kesehatan*, **3**: 162–167.

Prasetya, A.A.N.P.R., Suprpti, B., dan Shanti, B.D., 2019. Effectivity of Erythropoietin Alpha Compared to Erythropoietin Beta in Patients with Chronic Kidney Disease-Anemia on Hemodialysis. *Folia Medica*

Indonesiana, **55**: 82.

Price, S.A. dan Wilson, L.M., 2012. *Patofisiologi Konsep Klinis Proses-Proses Penyakit*, Edisi 6. ed. Routledge : JAKARTA., 2005.

Rascati, K.L., 2014. *Essentials of Pharmacoeconomics*, Second edition. ed. Wolters Kluwer Health/Lippincott Williams & Wilkins, Philadelphia.

RISKESDAS, 2018. 'Laporan Nasioanl Riset Kesehatan Dasar (RISKESDAS) 2018', . URL:
http://labdata.litbang.kemkes.go.id/images/download/laporan/RKD/2018/Laporan_Nasional_RKD2018_FINAL.pdf (diakses tanggal 5/6/2021).

Roggeri, D.P., Roggeri, A., dan Salomone, M., 2014. Chronic Kidney Disease: Evolution of Healthcare Costs and Resource Consumption from Predialysis to Dialysis in Piedmont Region, Italy. *Advances in Nephrology*, **2014**: 1–6.

Rottembourg, J., Tilleul, P., Deray, G., Lafuma, A., Zakin, L., Mahi, L., dkk., 2014. Cost of managing anemia in end-stage renal disease: the experience of five French dialysis centers. *The European Journal of Health Economics*, .

Ryu, S.-R., Park, S.K., Jung, J.Y., Kim, Y.H., Oh, Y.K., Yoo, T.H., dkk., 2017. The Prevalence and Management of Anemia in Chronic Kidney Disease Patients: Result from the KoreaN Cohort Study for Outcomes in Patients With Chronic Kidney Disease (KNOW-CKD). *Journal of Korean Medical Science*, **32**: 249.

Schonder, K.S., 2016. Chronic and End-Stage Renal Disease, dalam: Chisholm-

- Burns, M.A., Schwinghammer, T.L., Wells, B.G., Malone, P.M., Kolesar, J.M., dan DiPiro, J.T. (Editor), *Pharmacotherapy: Principles & Practice: Fourth Edition*. McGraw-Hill Education, US, hal. 399–426.
- Segall, L., Nistor, I., dan Covic, A., 2014. Heart Failure in Patients with Chronic Kidney Disease: A Systematic Integrative Review. *BioMed Research International*, **2014**: 1–21.
- Selim, M.F.M., Lotfy, E.E.M., Abd, L., Mohamed, E., dan Zahran, M.H., 2021. Assessment Of Erythropoietin Efficacy And Dosing In Hemodialysis Patients. *European Journal of Molecular & Clinical Medicine*, **8**: 9.
- Sihombing, J.P., 2019. Cost Effectiveness Analysis Eritropoetin α Ddibandingkan dengan Eritropoetin β Pada Pengobatan Anemia Pasien Penyakit Ginjal Kronik yang Menjalani Hemodialisa Rutin. *Universitas Gadjah Mada*, 202.
- Simanjuntak, E.Y. dan Halawa, B.A.S., 2019. Faktor-faktor yang Mempengaruhi Kepatuhan Pasien Gagal Ginjal kronis yang Menjalani Hemodialisis di RSUD Gunungsitoli Nias. *Indonesian Trust Health Journal*, **1**: 68–75.
- Singh, A.K., 2008. Anemia of Chronic Kidney Disease. *Clinical Journal of the American Society of Nephrology*, **3**: 3–6.
- Singh, N.P. dan Garg, N., 2017. Management of Anemia in Chronic Kidney Disease : Revisited. *The Association of Physicians of India*, .
- Smith, D.H., Gullion, C.M., Nichols, G., Keith, D.S., dan Brown, J.B., 2004. Cost of Medical Care for Chronic Kidney Disease and Comorbidity among Enrollees in a Large HMO Population. *Journal of the American Society of*

Nephrology, **15**: 1300–1306.

Somvanshi, S., Khan, N.Z., dan Ahmad, M., 2012. Anemia in chronic kidney disease patients. *Clinical Queries: Nephrology*, **1**: 198–204.

Sowinski, K.M., Churchwell, M.D., dan Decker, B.S., 2020. Chronic Kidney Disease, dalam: DiPiro, J.T. (Editor), *The 11th Edition of Pharmacotherapy: A Pathophysiologic Approach*. McGraw Hill Medical, New York, hal. 1904–1991.

Spoto, B., Pisano, A., dan Zoccali, C., 2016. Insulin resistance in chronic kidney disease: a systematic review. *American Journal of Physiology-Renal Physiology*, **311**: F1087–F1108.

Stauffer, M.E., 2014. Prevalence of Anemia in Chronic Kidney Disease in the United States.

Sudoyo, A.W., 2009. *Buku Ajar Ilmu Penyakit Dalam Jilid II*, V. ed. Interna Publishing : JAKARTA, Jakarta.

Trask, L.S., 2011. Pharmacoeconomics: Principles, Methods, and Applications, dalam: DiPiro, J., Talbert, R.L., Yee, G., Matzke, G., Wells, B., dan Posey, L.M. (Editor), *The 8th Edition of Pharmacotherapy: A Pathophysiologic Approach*. McGraw-Hill Publishing, New York, hal. 1–3.

Trisna, Y., 2016. 'Aplikasi Farmakoekonomi', . URL: <http://iai.id/news/artikel/aplikasi-farmakoekonomi> (diakses tanggal 16/3/2021).

USRDS, 2020. 'Unites States Renal Data System Annual Data Report 2020', *USRDS*. URL: <https://adr.usrds.org/> (diakses tanggal 6/12/2021).

- Vaidya, S.R. dan Aeddula, N.R., 2020. *Chronic Renal Failure*, StatPearls [Internet]. StatPearls Publishing.
- Vanholder, R., Davenport, A., Hannedouche, T., Kooman, J., Kribben, A., Lameire, N., dkk., 2012. Reimbursement of Dialysis: A Comparison of Seven Countries. *Journal of the American Society of Nephrology*, **23**: 1291–1298.
- Webster, A.C., Nagler, E.V., Morton, R.L., dan Masson, P., 2017. Chronic Kidney Disease. *The Lancet*, **389**: 1238–1252.
- Wells, B.G., DiPiro, J.T., Schwinghammer, T.L., dan DiPiro, C.V., 2015. *Pharmacotherapy Handbook*.
- WHO, 2015. The global prevalence of anaemia in 2011. *Geneva: World Health Organization*, .
- WHO, W.H.O. dan MSH, M.S. for H., 2007. 'Drug and Therapeutics Committee Training Course Session 6. Evaluating the Cost of Pharmaceuticals', . Dipresentasikan pada Rational Pharmaceutical Management Plus Program, U.S. Agency for International Development (USAID), Arlington, US, hal. 1–17.
- Widianti, C., Anggriani, Y., Kusumaeni, T., dan Meila, O., 2018. Analisis Efektivitas Biaya Penggunaan Eritropoetin (HEMAPO® , EPOTREX®, NEORECORMON®) Pada Pasien Hemodialisis Di RSUP Persahabatan 5.
- Yarnoff, B.O., Hoerger, T.J., Simpson, S.A., Pavkov, M.E., Burrows, N.R., Shrestha, S.S., dkk., 2016. The Cost-Effectiveness of Anemia Treatment for Persons with Chronic Kidney Disease. *PLOS ONE*, 14.

Zadrazil, J. dan Horak, P., 2015. Pathophysiology of anemia in chronic kidney diseases: A review. *Biomedical Papers*, **159**: 197–202.